Nabi-HB Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global hepatitis b prevalence, established use of immune globulins in prophylaxis, expansion of vaccination and prevention programs, availability of plasma fractionation technologies, increasing occupational exposure risks.

The growth in the forecast period can be attributed to expansion of hepatitis prevention initiatives, rising focus on high-risk population protection, increasing demand for emergency immunoprophylaxis, advancements in plasma purification methods, growing public health preparedness efforts. Major trends in the forecast period include increasing demand for passive immunization therapies, rising use of hbig in post-exposure prophylaxis, growing focus on infection prevention strategies, expansion of plasma-derived therapeutics, enhanced emphasis on rapid immune protection.

The increasing prevalence of hepatitis B is expected to drive the growth of the Nabi-HB market going forward. Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV), which can result in chronic liver disease and liver cancer. The rising incidence of hepatitis B is attributed to factors such as insufficient vaccination coverage, unprotected sexual activity, needle sharing among drug users, and limited access to healthcare in high-risk areas. Nabi-HB provides immediate, short-term protection against hepatitis B, particularly in high-risk situations such as post-exposure prophylaxis and during liver transplants. For instance, in August 2025, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in 2023, people aged 40-59 accounted for 48% of all acute hepatitis B cases. Therefore, the increasing prevalence of hepatitis B is driving the growth of the Nabi-HB market.

The rising aging population is expected to further propel the Nabi-HB market. An aging population refers to a demographic shift where the proportion of individuals aged 65 and older increases, often due to longer life expectancy and declining birth rates. This trend is driven by improvements in healthcare, living standards, and longevity. Nabi-HB supports the aging population by providing passive immunity against HBV, reducing the risk of chronic infection and its complications, which are more common in older adults due to weakened immune systems and increased susceptibility to viral infections. For example, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older, representing 19% of the total population, projected to rise to 22.1 million (27%) by 2072. Therefore, the aging population is driving growth in the Nabi-HB market.

The rising prevalence of chronic diseases is also expected to boost the Nabi-HB market. Chronic diseases are long-term conditions that require ongoing management, including treatment and preventive care, and their prevalence is increasing due to aging populations, unhealthy lifestyles, environmental factors, and greater exposure to risk factors such as pollution and stress. Nabi-HB benefits individuals with chronic conditions by providing passive immunity against HBV, preventing chronic HBV infection and its complications, such as liver cirrhosis and liver cancer, which are more common in patients with chronic viral infections. For instance, in April 2025, the CDC reported that 76.4% of US adults - approximately 194 million people - had one or more chronic conditions in 2023, including 59.5%, 78.4%, and 93% of young, midlife, and older adults, respectively. Therefore, the rising prevalence of chronic diseases is driving the growth of the Nabi-HB market.

Major companies operating in the nabi-hb market are ADMA Biologics Inc.

North America was the largest region in the nabi-hb market in 2025. The regions covered in the nabi-hb market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nabi-hb market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the nabi-hb market by increasing costs of imported plasma-derived raw materials, cold-chain logistics equipment, sterile packaging systems, and biopharmaceutical processing inputs. North America and Europe are most affected due to dependence on international plasma sourcing and fractionation infrastructure. These tariffs are contributing to higher procurement and distribution costs for immune globulin products. However, they are also encouraging domestic plasma collection expansion, regional fractionation investments, and improved self-sufficiency in plasma-derived therapeutic production.

The nabi-hb market research report is one of a series of new reports that provides nabi-hb market statistics, including nabi-hb industry global market size, regional shares, competitors with a nabi-hb market share, detailed nabi-hb market segments, market trends and opportunities, and any further data you may need to thrive in the nabi-hb industry. This nabi-hb market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nabi-HB is a human hepatitis B immune globulin (HBIG) used for post-exposure prophylaxis against hepatitis B virus (HBV) infection, especially in individuals exposed through needlesticks, surgery, or other contact. It provides passive immunity by delivering antibodies against HBV, offering temporary protection until the body mounts its own immune response.

The primary indications for Nabi-HB include post-exposure prophylaxis and prevention in high-risk populations. Post-exposure prophylaxis involves administering preventive treatment after potential exposure to reduce the risk of infection. Nabi-HB is available as an injectable solution and in prefilled syringes and is distributed through hospitals, specialty clinics, public health agencies, and pharmacies. It is used by infants and adult patients.

The nabi-hb market consists of sales of combination vaccines, immunoglobulins, flu vaccines and pneumococcal vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.